CRISPR Therapeutics Price Target Revised Up 14.61% to $82.91 Share

The average one-year price target for CRISPR Therapeutics (CRSP) has been revised to $82.91/share, a 14.61% increase from the prior estimate of $72.34. This represents an increase of 61.59% from the latest reported closing price of $51.31/share. There are 621 funds or institutions reporting positions in CRSP, with ARK Investment Management holding 9,787K shares, representing 10.27% ownership of the company.